In the melanoma group, 4 of 10 patients had a BRAF V600E mutation, 2 were stage IIIA, 2 were stage IIIB, 1 was stage IIID and 5 were stage IV at the time of initiating ICIs. The gene discussed is BRAF; the disease is melanoma.